GLP1R and peripheral arterial disease: <h4>Background</h4>The American Diabetes Association recommends the use of glucagon-like-peptide-1 receptor agonists (GLP1-RAs) (e.g., Ozempic) for patients with atherosclerotic cardiovascular disease, including peripheral artery disease.